# Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

> **NCT02956967** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 171 (actual)

## Conditions studied

- Non-Interventional Study

## Interventions

- **OTHER:** Overall satisfaction questionnaires of home use of Nivestim

## Key facts

- **NCT ID:** NCT02956967
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-23
- **Primary completion:** 2016-12-12
- **Final completion:** 2016-12-12
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2019-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02956967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02956967, "Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02956967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*